Project Grant R01CA311117
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $658K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Scottsdale, AZ 85259, USA
Similar Awards
- Federal Grant Award Summary Mayo Clinic Arizona has been awarded $156,080 by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) to conduct research on the functional role of KLRG1+ conventional helper T cells in the tumor microenvironment. The project, which commenced on December 25, 2025, and will conclude on July 31, 2028, aims to define how killer cell lectin-like receptor G1 (KLRG1) expressing CD4+ T cells contribute to cancer progression and immune...
- Federal Grant Award Summary Mayo Clinic Jacksonville received a $498,582 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) awarded June 1, 2026, with completion scheduled for May 31, 2031. The grant funds fundamental research investigating acetylation as a post-translational modification mechanism that regulates T cell receptor (TCR) signaling to overcome T cell exhaustion in cancer immunotherapy. The research aims to establish SIRT2 (silent...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1,098,920 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 13, 2025, with completion targeted for April 30, 2030. The research focuses on understanding the transcriptional and epigenetic control of CD8+ tumor-infiltrating lymphocytes (TILs) and tumor memory cells to enhance anti-tumor immune responses....
- Federal Project Grant Award Summary Mayo Clinic received a $558,016 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded May 8, 2026, with completion targeted for April 30, 2031. The project investigates accelerated biological aging and immunosenescence as drivers of racial disparities in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma (MM). The research aims to understand why African American...
- Federal Grant Award Summary Mayo Clinic received a $484,803 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 18, 2025, with completion scheduled for July 31, 2030. This research initiative focuses on elucidating glioma risk and improving patient outcomes by integrating germline and somatic genetics analysis. The project addresses critical gaps in understanding the functional relevance of 30 known germline...
- Federal Grant Award Summary Mayo Clinic received a $367,731 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded May 12, 2026, with a completion date of April 30, 2031. The grant supports research investigating the role of ADAR1P110 (a nuclear isoform of adenosine deaminase acting on RNA) in RNA primer editing during DNA replication and its potential as a therapeutic target for breast cancer, particularly triple-negative...
- Federal Project Grant Award Summary Mayo Clinic has been awarded $741,738 by the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) for a five-year project (June 1, 2026–May 31, 2031) investigating hypomorphic BRCA1 and BRCA2 variants and their role in cancer risk and treatment response. The research will establish the functional and clinical characteristics of reduced penetrance pathogenic variants (RPPVs)—a newly identified category of cancer risk...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Grant Award Summary The National Cancer Institute awarded Mayo Clinic a $659,028 Research Project Grant (R01) under the Cancer Treatment Research program (CFDA 93.395) on May 20, 2026, with a completion date of April 30, 2031. This research initiative focuses on developing novel multi-modality treatment combinations to improve therapeutic outcomes for high-risk Ewing sarcoma patients, specifically those with STAG2 (Stromal Antigen 2) loss who experience significantly worse prognoses. The...
- Federal Grant Award Summary Mayo Clinic received a $667,710 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective March 20, 2026 through February 28, 2031. This award supports a randomized Phase 2 clinical trial designed to refine personalized treatment strategies for patients with oligometastatic castration-sensitive prostate cancer (OMCSPC) by integrating blood-based biomarkers with stereotactic body radiation therapy...